Multiple Myeloma Coverage from Every Angle


SOHO 2023: Final Overall Survival Trial Update on Combination Therapy in Myeloma
Study in France and Algeria: Unexpected Survival Similarities After ASCT in Myeloma
SOHO 2023: Personalized, Multidisciplinary Approach to Managing Myeloma in Frail Adults
Motixafortide Plus Filgrastim Approved by FDA for ASCT in Multiple Myeloma
Cryopreserved Autologous Peripheral Blood Hematopoietic Cells: Patterns in Use and Related Costs
Can Phenotypic Patterns in Multiple Myeloma Correlate With Clinical Outcomes?
Potential Immunogenic Cell Death–Related Predictor of Therapeutic Response in Myeloma
Researchers Focus on Affinity Tuning of CAR T Cells in Myeloma to Reduce Toxicity
Underrepresentation of Non-White Patients in Multiple Myeloma Clinical Trials
FDA Grants Accelerated Approval to Elranatamab-bcmm in Treatment of Relapsed or Refractory Myeloma
FDA Approves Talquetamab-tgvs for Treatment of Relapsed or Refractory Multiple Myeloma
Bortezomib-Induced Peripheral Neuropathy in Black Patients With Newly Diagnosed Myeloma
Use of Teclistamab in Patients With Myeloma Who Had Received Anti-BCMA Therapy
Real-World Analysis of Bridging Therapy Before CAR T-Cell Therapy for Resistant Myeloma
DREAMM-3 Trial: Belantamab Mafodotin Versus Pomalidomide Plus Dexamethasone in Relapsed Myeloma
Long-Terms Results With Isatuximab-Based Regimen for 1q21-Positive Patients With Myeloma
Final Analysis From CARTITUDE-1 Trial of Ciltacabtagene Autoleucel in Resistant Myeloma
Observations on Global Disparities in Toxicity From Myeloma Treatment
Does Bispecific Antibody Therapy for Relpased Multiple Myeloma Pose a Risk of Infection?
5-Year Follow-up of LEGEND-2 Trial of Immunotherapy for Resistant Myeloma
Can Clonal Diversity Complement MRD Assessment in Predicting Outcomes in Myeloma?
CARTITUDE-4 Shows Potential of Ciltacabtagene Autoleucel in Myeloma After First Relapse
Isatuximab With and Without Lenalidomide Under Study in High-Risk Smoldering Myeloma
Extended Follow-up From MagnetisMM-3 on Use of Elranatamab in Resistant Myeloma
Update From Phase II MonumenTAL-1 Study of Talquetamab in Resistant Myeloma
EHA 2023: Use of Idecabtagene Vicleucel in High-Risk Subgroups With Resistant Myeloma
ASCO 2023: New BCMA-Directed CAR T-Cell Therapy Under Study in Resistant Myeloma
EHA 2023: MRD as a Surveillance Tool in MASTER Trial of Quadruplet Therapy for Multiple Myeloma
ASCO 2023: Infection Profile and Immune Function With Talquetamab Monotherapy for Myeloma
EHA 2023: Research Explores T-Cell Exhaustion and CAR T-Cell Therapy for Myeloma
ASCO 2023: Maintenance Triplet Regimen for High-Risk Myeloma
EHA 2023: Therapeutic Implications of Distinct T-Cell Profile of Older Patients With Multiple Myeloma
ASCO 2023: New Data on Efficacy, Safety, Dosage of Bispecific Antibody Linvoseltamab
EHA 2023: Could the Oxidative Phosphorylation Pathway Be a Therapeutic Target in Multiple Myeloma?
ASCO 2023: CARTITUDE-4 Reports Benefit of Ciltacabtagene Autoleucel in Lenalidomide-Refractory Myeloma
ASCO 2023: Elotuzumab-Based Combination Regimen Under Study in First-Line Setting for Myeloma
ASCO 2023: Preliminary Results With Teclistamab Plus Talquetamab for Resistant Multiple Myeloma
ASCO 2023: TRIMM-2 Update Supports Steroid-Sparing Regimen for Resistant Myeloma
Bone Marrow Assessment of MRD as a Prognostic Tool in Multiple Myeloma
What We Know About the Association Among Diet, the Microbiome, and Multiple Myeloma
Treatment Algorithm for Patients With Myeloma and Light Chain Cast Nephropathy
Predicting Benefit of Elotuzumab in Myeloma: Novel Scoring System Focuses on Lymphocyte Counts and B2M
Next-Generation Sequencing and MRD Negativity in Multiple Myeloma
POMACE Phase II Trial in Myeloma: Combination of Bortezomib, Pomalidomide, and Dexamethasone
AACR 2023: Checkpoint Blockade and Multiple Myeloma–Specific Targeting May Enhance NK Cell Responses
AACR 2023: Cellular Membrane Lipid-Extracted Nanoliposomes in Multiple Myeloma
AACR 2023: Racial and Socioeconomic Influences on Access to Care in Multiple Myeloma
AACR 2023: First-in-Human Study Results on New Bispecific Antibody in Resistant Myeloma
AACR 2023: Does Race Play a Role in Progression of Myeloma Among Patients Being Treated for Diabetes?
AACR 2023: Strategies to Overcome Resistance to Chemotherapy in Patients With Myeloma
FDA Brief: Cell Therapy Approved to Reduce Infection Risk After Stem Cell Transplantation
AACR 2023: 3D Organoid Model as a Conduit for Studying Multiple Myeloma
Study Identifies Novel Diagnostic Tool for Patients With Multiple Myeloma
Exploring the Utility of Liquid Biopsy for Disease Evaluation of Multiple Myeloma
Final Analysis of PLEIADES and EQUULEUS: Treatment Insights on Daratumumab-Based Regimen
NCCN 2023: A Rare Case of Intratubular Cytoplasmic Amyloidosis in a Patient Without Myeloma
NCCN 2023: Update on Managing Resistant Myeloma
Are Carfilzomib-Treated Patients With Myeloma at Risk for Thrombotic Microangiopathy?
Novel Anti-CD38 Antibody Quadruplet Regimen for Newly Diagnosed Multiple Myeloma
Immunoglobulin J Chain: Potential Target of T-Cell Receptor–Based Therapy in Myeloma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.